Prescient Therapeutics licenses Pennsylvania and Oxford university technologies to create universal cell therapy platform
The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell...
The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.